Finally, treatment with povorcitinib led to the differential expression of CXCL10, GZMH, IL12B, IL2RA, and TNFSF11, whose corresponding genes were previously shown to be highly expressed in lesional skin from patients with HS compared with healthy controls [9]. The gene discussed is GZMH; the disease is histiocytic sarcoma.